Drug intelligence / Profile preview

UIC201603

Development stage: Phase 1
Lead developer: Korea United Pharm

Overview

UIC201603 is an investigational pharmaceutical compound developed by Korea United Pharm. It has been studied in phase 1 clinical trials, primarily to evaluate its safety and pharmacokinetic profile, both alone and in combination with another investigational agent, UIC201604. The specific mechanism of action, molecular target(s), therapeutic area(s), and active indications for UIC201603 have not been publicly disclosed as of the latest available data. The drug has not received regulatory approval for any indication and remains at an early stage of development[1][2][3].

Beyond the preview

Go deeper on UIC201603.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UIC201603.